Skip to main content
GoodMoatv1.3
Sign in
INCY logo

INCY

CompareEarnings: Aug 31, 2026

Incyte Corp

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

Did you know?

Holds 89.3x more cash than debt — a strong balance sheet.

Current Price

$96.91

+1.72%

GoodMoat Value

$271.40

180.1% undervalued
Profile
Valuation (TTM)
Market Cap$19.29B
P/E13.47
EV$14.21B
P/B3.73
Shares Out199.01M
P/Sales3.60
Revenue$5.36B
EV/EBITDA8.18

Incyte Corp (INCY) Valuation

INCY Fair Value Estimate

$271.40180.1% undervalued

Blended fair value estimate based on DCF, Graham Number, and earnings-based models.

INCY Valuation Metrics

FCF$1.35B
FCF Growth Rate13.53%
EPS Growth (CAGR)19.27%
WACC10.00%

INCY Valuation & Fair Value Analysis

Incyte Corp (INCY) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for Incyte Corp is $271.40. The current stock price is $96.91, suggesting the stock is 180.1% undervalued.

The price-to-earnings (P/E) ratio is 13.47. Price-to-book ratio is 3.73. Price-to-sales ratio is 3.60. Enterprise value to EBITDA is 8.18. PEG ratio is 0.16.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Incyte Corp's intrinsic value.